The Patent Cliff Portfolio: Who Is Exposed Before 2029

Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/

Merck’s Keytruda earned $31.68 billion in 2025. That is 48.7% of the company’s $65.01 billion in sales (calculated from [1]). A key US patent for Keytruda is expected to expire at the end of 2028 [3]. Bristol Myers Squibb faces a similar problem: Eliquis and Opdivo together made 50.6% of its 2025 revenue (calculated from [8][9]). This guide shows how to find, measure and compare that exposure.

This article gives information and analysis. It does not give investment advice. We are not financial advisors. Patent dates are public, so a date alone rarely gives an edge. The useful question is how much revenue a company loses compared with what it can replace.

The Short Answer: What Is a Patent Cliff Portfolio?

A patent cliff portfolio is a watchlist of companies ranked by how much revenue they lose when key drugs lose exclusivity. It has three parts: the exposed revenue, the date of generic or biosimilar entry, and the revenue that can replace the loss.

Definition: Loss of Exclusivity (LOE)

Loss of exclusivity (LOE) is the date when a drug no longer has patent or regulatory protection that blocks competitors. After that date, generic or biosimilar versions can enter the market. Pfizer states that it expects “a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030” [11].

Definition: Cliff Exposure Ratio (CER)

The Cliff Exposure Ratio is an original screening metric used in this article. It is not an industry standard. It equals the annual revenue of the drugs that face LOE divided by total company revenue. A higher ratio means one event can change the whole company.

How Big Is the 2025-2030 Patent Cliff?

Published estimates range from about $230 billion to more than $400 billion. The figures differ because each analyst uses a different scope, region and method.

What Do the Main Estimates Say?

  • Evaluate estimates that more than $300 billion in global prescription revenue will lose exclusivity between 2025 and 2030 [22].
  • GlobalData puts the US-only figure at more than $230 billion for the same period [22].
  • DrugPatentWatch has published a range of $200 billion to $400 billion. It says the range reflects uncertainty about litigation, biosimilar timing and price negotiation [23].

These are estimates of revenue exposed, not forecasts of revenue lost. The gap between a patent date and real competitor entry can be long. Settlements, appeals and launch delays all move the date.

Why Do Estimates Differ?

Three choices change the total. Some analysts count global sales and others count US sales. Some count a drug when its first patent expires and others count it when competitors actually launch. Some include products that have settled generic entry dates and others do not. Compare two estimates only after you check these choices.

“We recorded revenues of more than $1 billion for each of 12 products that collectively accounted for 65% of Total revenues in 2025.” (Pfizer Inc., Form 10-K for fiscal year 2025) [11]

Methodology: How We Built the Exposure Data

What Data We Analyzed

We used fiscal-year 2025 figures from company filings and earnings releases, and Novartis’s first-half 2026 report. We used court and company statements for patent and settlement dates. We used trade and analyst sources only where no primary source was available. The review date is October 6, 2026.

How We Calculated the Numbers

Every figure marked “calculated” is our own arithmetic. We divided product revenue by total company revenue, rounded to one decimal place. We used reported figures in US dollars. We did not adjust for currency.

Inclusion Rules

We included a drug if the company or a court filing ties it to a named exclusivity event. We excluded drugs where we found no date from a reliable source.

Limits of This Analysis

Product revenue under alliance accounting can differ by partner. BMS reports Eliquis revenue for the BMS-Pfizer alliance on a global basis [9]. Pfizer reports Eliquis as 13% of its own total revenue [11]. The two numbers describe different shares and should not be added together. We also used rounded inputs, so ratios can move by a tenth of a point.

The Five Findings That Matter

  1. Keytruda was 48.7% of Merck’s 2025 sales (calculated from [1]). Its key US patent is expected to expire at the end of 2028 [3].
  2. Eliquis and Opdivo together were 50.6% of BMS’s 2025 revenue (calculated from [8][9]).
  3. Stelara sales fell 41.3%, from $10.36 billion to $6.08 billion, in the first full year after biosimilar entry [13].
  4. Novartis’s Entresto sales fell 46% in the first half of 2026 compared with the first half of 2025, from $4.62 billion to $2.49 billion [15].
  5. AbbVie’s 2025 revenue of $61.16 billion was 5.4% above its 2022 level of $58.05 billion, even after Humira fell sharply (calculated from [19][20]).

Patent Timeline: Dates That Set the Clock

The table lists confirmed and expected exclusivity events. “Expected” means the company, court or reporter gave a date that could still change.

DrugCompanyEventStatusSource
Humira (adalimumab)AbbVieUS biosimilar competition from 2023Confirmed[20]
Stelara (ustekinumab)Johnson & JohnsonSeveral US biosimilars launched in 2025Confirmed[13]
Entresto (sacubitril/valsartan)NovartisUS generic entry in Q3 2025Confirmed[16]
Ibrance (palbociclib)PfizerLOE in 2027Expected[12]
Xtandi (enzalutamide)Pfizer / AstellasLOE expected in 2027Expected[29]
Eliquis (apixaban)BMS / PfizerEarliest generic launch April 1, 2028Expected; set by court ruling and settlements[6][7]
Keytruda (pembrolizumab)MerckKey US patent expires at end of 2028; Europe expected 2031Expected[3]

Eliquis: Why April 1, 2028?

The Federal Circuit affirmed a district court decision that the composition of matter patent (US 6,967,208) and a formulation patent (US 9,326,945) for Eliquis were valid and infringed. BMS and Pfizer said the earliest generic launch is April 1, 2028, “subject to additional appeals and challenges” [6]. Four generic companies, Sigmapharm, Sunshine Lake, Hec Pharm and Unichem, chose to litigate instead of settle [7]. As of October 6, 2026, that date is about 17 months away (calculated).

Keytruda: What Happens at the End of 2028?

Fierce Pharma reported that Merck expects a key US patent to expire at the end of 2028, and that European exclusivity runs to 2031 [3]. The same report names Celltrion, Samsung Bioepis and Amgen as developers of late-stage biosimilars [3]. That report was written before a 2025 law changed which drugs the government can negotiate prices for. Its statement that Keytruda would face Medicare price setting from 2028 is outdated (see the policy section below).

Keytruda Qlex: The Subcutaneous Defense

Merck launched the subcutaneous version, Keytruda Qlex, in the US after an FDA approval in September 2025 [5]. Merck reported $40 million in Qlex sales for 2025 [1]. A Merck spokesperson said the Qlex price is “on par” with the intravenous version, which costs about $200,000 per year, according to a report summarized by Salud y Farmacos [30]. Whether Qlex slows biosimilar uptake is untested. We treat it as a risk factor, not a fact.

Case Studies: What Happened After Humira, Stelara and Entresto?

Three recent cases give real erosion rates. They differ in drug class and market, so we treat them as reference points, not predictions.

DrugPeriodRevenue changeSource
Humira2023 vs 2022Global sales down 32% (constant currency)[20]
Humira2024 vs 2023Down 37.6% to $8.99 billion[21]
Humira2025 vs 2024Down 49% (constant currency) to $4.54 billion[18][19]
Stelara2025 vs 2024Down 41.3% to $6.08 billion[13]
EntrestoH1 2026 vs H1 2025Down 46% to $2.49 billion[15]

How Did AbbVie Survive the Humira Cliff?

AbbVie replaced Humira with two newer immunology drugs. In 2025, Skyrizi earned $17.56 billion and Rinvoq earned $8.30 billion, while Humira earned $4.54 billion [18]. Skyrizi and Rinvoq together were $25.87 billion, or 5.7 times Humira’s 2025 sales (calculated from [18]). AbbVie’s total revenue fell 6.4% in 2023, then reached $61.16 billion in 2025 [19][20].

Lesson for Investors

AbbVie had two drugs in the same therapeutic area ready before the cliff. That is one data point. It does not show that other companies can repeat it.

Johnson & Johnson and Stelara: Did Diversification Work?

J&J’s 2025 worldwide sales were $94.2 billion, up 5.3% on an operational basis, despite a Stelara headwind of about 620 basis points [14]. Oncology sales rose 22.1% to $25.4 billion [13]. Darzalex alone earned $14.35 billion in 2025 [33]. Stelara lost $4.28 billion in one year (calculated from [13]), and the company still grew.

Why the Size of the Company Matters

Stelara was 6.5% of J&J’s 2025 sales (calculated from [13][14]). A loss of that size can be absorbed. A loss near 50% of revenue cannot be absorbed the same way.

Novartis and Entresto: A Cliff Already in the Numbers

Novartis reported Entresto sales of $1.25 billion in Q3 2025, down 43%, after US generic entry [16]. In Q2 2026, sales fell 50% to $1.18 billion [15]. Novartis said it was in litigation with a generic manufacturer to protect its Entresto IP [16]. Entresto earned $7.8 billion in 2025 [17], or 14.3% of Novartis’s $54.5 billion in sales (calculated from [17][31]).

Who Is Exposed? Merck, BMS and Pfizer

The Cliff Exposure Ratio Table

The table shows the Cliff Exposure Ratio (CER) for six companies. “Pre-cliff” means the main exposed drug has not yet lost exclusivity. “Post-cliff” means it already has.

Company2025 revenueExposed product2025 product revenueCER (calculated)StageSource
Merck$65.01BKeytruda / Keytruda Qlex$31.68B48.7%Pre-cliff[1]
Bristol Myers Squibb$48.2BEliquis + Opdivo$14.4B + $10.0B50.6%Pre-cliff[8][9]
Pfizer$62.58BEliquis (Pfizer share)About $8.1B (13% of revenue)13.0% (Eliquis only)Pre-cliff[11][12]
Novartis$54.5BEntresto$7.8B14.3%Post-cliff[17][31]
Johnson & Johnson$94.2BStelara$6.08B6.5%Post-cliff[13][14]
AbbVie$61.16BHumira$4.54B7.4%Post-cliff[18][19]

The Pfizer row counts only Eliquis. Pfizer also expects LOE for Ibrance and Xtandi in 2027 [12][29], but we did not find a reliable 2025 revenue figure for them, so they are not in the ratio. Pfizer’s own 2026 guidance includes an LOE impact of $1.5 billion [12].

Merck: One Drug, Two Years

Merck guided 2026 sales of $65.5 billion to $67.0 billion [1]. Keytruda grew 7% in 2025 [1]. Gardasil sales fell 39% to $5.2 billion in the same year [1], which shows Merck has already absorbed one large decline. Merck has also been buying assets. IQVIA lists Merck/Terns at $6.7 billion among 2026 deals [25].

What Merck Must Replace

A loss of 20% to 45% of Keytruda sales would remove $6.3 billion to $14.3 billion a year at 2025 levels (calculated). The scenario section below shows the full range.

Bristol Myers Squibb: Two Drugs, One Half of Revenue

BMS’s 2025 revenue was $48.2 billion, flat versus 2024. Its Growth Portfolio earned $26.4 billion, up 17%, while its legacy portfolio fell 15% to $21.8 billion [8]. Eliquis earned $14.4 billion and Opdivo $10.0 billion [9]. Eliquis holds about 75% of new US prescriptions in its class, according to an earnings summary [10]. The same summary says BMS expects 2027 Eliquis sales to be $1.5 billion to $2 billion lower than in 2026 [10].

The Dependency Gap

BMS’s growth drugs are already larger than its legacy drugs. Yet the two drugs that will face LOE still produce half of company revenue. That gap is the key number for this company.

Pfizer: Spread Across Many Products

Pfizer’s 2025 revenue was $62.58 billion, down 2% [12]. Twelve products earned more than $1 billion each and made up 65% of revenue [11]. Eliquis alone was 13% [11]. Pfizer’s exposure is wider and shallower than Merck’s. It paid about $10 billion for Metsera in November 2025 to add obesity programs [28].

Scenario Analysis: What Could Keytruda Erosion Look Like?

The scenarios below apply real first-year erosion rates from other drugs to Keytruda’s 2025 sales of $31.68 billion. This is an illustration, not a forecast.

AnalogErosion rateKeytruda revenue lost (calculated)Share of Merck 2025 sales (calculated)
Humira, 2023 [20]32%$10.1B15.6%
Stelara, 2025 [13]41.3%$13.1B20.1%
Entresto, H1 2026 [15]46%$14.6B22.4%

What the Scenarios Leave Out

  • Keytruda sales may grow before 2028, which raises the base.
  • Humira and Stelara are self-injected immunology drugs. Keytruda is an infused cancer drug given in clinics. Switching behavior may differ.
  • Biosimilar launch timing is not known. A launch delay reduces first-year loss.
  • Qlex may move patients to a product that has separate protection.

Why Do Patent Expiry Dates Mislead?

A patent expiry date is not a market entry date. Court rulings, settlements, regulatory exclusivity and manufacturing readiness all change the real date.

Settlement Dates vs. Patent Dates

Eliquis shows the gap clearly. Court and settlement terms set April 1, 2028 as the earliest generic launch [6]. One reporter notes the underlying patents expire in November 2026 and February 2031 [32]. Treat the second source with care, because it is a secondary summary. The point is that investors should track the actual entry date, not the headline expiry.

Did Medicare Negotiation Change the Keytruda Timeline?

Yes. CMS published the 2028 negotiation list on January 27, 2026. It included 15 drugs, five from Part B [4]. Milliman reports that an expansion of the orphan drug exclusion delays Opdivo and Keytruda until later price applicability years [4]. Earlier reports that Merck expected Keytruda price setting in 2028 [3] no longer match this list.

Why Policy Dates Matter for Valuation

A price cut and a patent loss are separate events. Each has its own date. A model that merges them can overstate or understate near-term revenue.

How Does M&A Change the Cliff Picture?

Large companies replace lost revenue by buying assets. Deal volume in 2026 is high, but trackers disagree on the totals.

What Do the Deal Trackers Show?

TrackerFindingSource
PwCQ1 2026 deal value above $65 billion, with 16 deals of $1 billion or more[24]
PitchBook (via Biopharma Wire)$106 billion across 201 transactions by mid-June 2026[27]
PharmaDossier (STAT cohort)33 deals of $1 billion or more, about $134 billion, through June 22, 2026; 26 such deals worth $112 billion in all of 2025[26]

The three totals differ because they count different deals and use different cut-off dates. Use the range, $106 billion to $134 billion, as a mid-2026 estimate.

Which Deals Were Largest?

IQVIA lists three 2026 deals above $10 billion: Sun Pharma/Organon at $11.8 billion, AbbVie/Apogee at $10.9 billion and GSK/Nuvalent at $10.6 billion [25]. IQVIA also reports no deal above $30 billion so far in 2026 [25]. Eli Lilly made nine acquisitions above $250 million and deployed about $26 billion [25].

What This Means for Brand Manufacturers

Companies with the highest ratios have the strongest reason to buy. A high ratio plus a large cash balance often signals deal activity. A high ratio plus high debt signals more risk. BMS reduced net debt from $38.5 billion to $34.0 billion during 2025 [9].

How to Build a Patent Cliff Portfolio: A Screening Checklist

Step 1: Measure the Exposure

Find the revenue of each drug with a named LOE date. Divide it by total company revenue. Use the company’s 10-K, not a news summary.

Step 2: Verify the Date

Check the patent term, any settlement terms, and any pending appeal. DrugPatentWatch lists patents and litigation records for drugs, which helps you find the patents to verify. Confirm each date against a court ruling or company statement, as we did for Eliquis.

Step 3: Count the Replacements

List products launched in the last three years, and note their growth. Compare their combined revenue with the exposed revenue. BMS’s Growth Portfolio ($26.4 billion) versus its legacy portfolio ($21.8 billion) is an example of this test [8].

Step 4: Check Lifecycle Moves

Look for new formulations, new indications and delivery changes. Keytruda Qlex is one example [5]. Ask whether the new version has its own patent and whether doctors switch to it.

Step 5: Check Policy Risk

Look at whether the drug is on a Medicare negotiation list. Pfizer names Medicare price setting (IRA) and Most Favored Nation pricing as risks to its revenue [11].

Step 6: Look at the Other Side of the Trade

Generic and biosimilar firms gain when a cliff opens. For Eliquis, FDA has approved generic applications from Micro Labs and Mylan, which still must wait for the launch date [34]. For Keytruda, Celltrion, Samsung Bioepis and Amgen have late-stage biosimilars [3]. Their gain depends on price, share and the number of rivals. We do not give a view on any of these companies.

What Are the Risks of a Patent Cliff Strategy?

Dates Are Already Public

Analysts, funds and companies all read the same filings. A known date is likely to be in the price already. We did not test this, so we flag it as a question, not a finding.

Forecasts Fail

Appeals, settlements and new indications move dates. The Eliquis date came from a 2021 ruling and still carried an appeal caveat [6].

Erosion Rates Vary

Our three analogs range from 32% to 46% in the first year. A real result can fall outside that range.

Key Takeaways

  • Published estimates of revenue exposed to LOE between 2025 and 2030 range from more than $230 billion (US only) to $300 billion or more (global) [22].
  • Keytruda was 48.7% of Merck’s 2025 sales. Its key US patent is expected to expire at the end of 2028 [1][3].
  • Eliquis and Opdivo made 50.6% of BMS’s 2025 revenue. The earliest US generic Eliquis launch is April 1, 2028 [6][8][9].
  • First-year erosion in three recent cases ran from 32% to 46% [13][15][20].
  • AbbVie’s 2025 revenue was 5.4% above 2022, after Humira’s loss [19][20].
  • Keytruda and Opdivo are not on the 2028 Medicare negotiation list [4].
  • Mid-2026 biopharma deal totals range from $106 billion to $134 billion, depending on the tracker [26][27].
  • The Cliff Exposure Ratio compares exposed revenue with total revenue. It needs a second test: how much new revenue can replace the loss.

FAQ

What is the pharmaceutical patent cliff?

It is the period when many high-revenue drugs lose patent or regulatory exclusivity close together. Pfizer expects a significant reduction in revenue from such expiries in 2026 through 2030 [11].

When does Keytruda lose US patent protection?

A key US patent is expected to expire at the end of 2028. European exclusivity is expected to last until 2031 [3].

When can generic Eliquis launch in the US?

BMS and Pfizer say the earliest date is April 1, 2028, subject to additional appeals and challenges [6].

How fast do sales fall after exclusivity ends?

Humira fell 32% in 2023 [20]. Stelara fell 41.3% in 2025 [13]. Entresto fell 46% in the first half of 2026 against the first half of 2025 [15]. These periods differ, so the rates are not directly comparable.

Did AbbVie recover from the Humira cliff?

Revenue did. AbbVie earned $61.16 billion in 2025 against $58.05 billion in 2022 [19][20]. Skyrizi and Rinvoq together earned $25.87 billion in 2025 (calculated from [18]).

Is Keytruda on the 2028 Medicare negotiation list?

No. Milliman reports that Keytruda and Opdivo were delayed to later price applicability years [4].

How much revenue is at risk through 2030?

Estimates range from more than $230 billion for the US alone to more than $300 billion globally [22]. DrugPatentWatch has published a range of $200 billion to $400 billion [23].

Who is developing Keytruda biosimilars?

Fierce Pharma named Celltrion, Samsung Bioepis and Amgen among companies with late-stage biosimilars [3]. Check current regulatory status before relying on this list, because the report may be out of date.

How much has pharma spent on M&A in 2026?

Estimates for the first half range from $106 billion (PitchBook) to about $134 billion (STAT cohort via PharmaDossier) [26][27].

Can a patent expiry date alone guide an investment?

Expiry dates are public information. The more useful variables are the exposure ratio, the replacement pipeline and the real entry date. This is analysis and not investment advice.

References

  1. Merck & Co., Inc. (2026, February 3). Merck announces fourth-quarter and full-year 2025 financial results. Merck. https://www.merck.com/news/merck-highlights-progress-advancing-broad-diverse-pipeline/
  2. Merck & Co., Inc. (2026). Form 10-K for fiscal year 2025. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm
  3. Fierce Pharma. (n.d.). Merck expects oncology king Keytruda to face IRA ‘price setting’ process starting in 2026. https://www.fiercepharma.com/pharma/merck-expects-keytruda-fall-ira-price-cuts-2028
  4. Milliman. (2026). 4 key takeaways from the third round of drugs selected for Medicare drug price negotiation. https://www.milliman.com/en-GB/insight/key-takeaways-third-medicare-drug-price-negotiation
  5. Precision Medicine Online. (2026). Merck Q4 and full-year 2025 results. https://www.precisionmedicineonline.com/node/46201
  6. Bristol-Myers Squibb-Pfizer Alliance. (2021, September 3). Statement on Federal Circuit decision upholding the Eliquis patents. Pfizer. https://www.pfizer.com/news/announcements/bristol-myers-squibb-pfizer-alliance-pleased-decision-us-court-appeals-federal
  7. FDAnews. (2021). BMS, Pfizer snag appeals court victory for blockbuster Eliquis. https://fdanews.com/articles/204340-bms-pfizer-snag-appeals-court-victory-for-blockbuster-eliquis
  8. Pharmaceutical Technology. (2026). BMS reports flat revenue growth in 2025. https://www.pharmaceutical-technology.com/news/bms-flat-revenue-growth-2025/
  9. Rivkin. (2026). Bristol-Myers Squibb (BMY:NASDAQ) full-year 2025 summary. https://rivkin.com.au/?p=35009
  10. AlphaSense. (2026). Bristol-Myers Squibb Q4 2025 earnings analysis and highlights. https://www.alpha-sense.com/earnings/bmy
  11. Pfizer Inc. (2026). Form 10-K for fiscal year 2025. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/pfe-20251231.htm
  12. Precision Medicine Online. (2026). Pfizer reports 9 percent increase in Q4 oncology revenue as Ibrance patent cliff looms. https://www.precisionmedicineonline.com/node/46216
  13. Johnson & Johnson. (2026). Form 10-K for fiscal year 2025. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/200406/000020040626000016/jnj-20251228.htm
  14. MarketBeat. (2026, January 21). Johnson & Johnson Q4 earnings call highlights. https://www.marketbeat.com/instant-alerts/johnson-johnson-q4-earnings-call-highlights-2026-01-21/
  15. Novartis AG. (2026). Form 6-K, Q2 2026 results. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/0001114448/000111444826000012/nvs-20260630-99_2.htm
  16. Novartis AG. (2026). Form 6-K, fiscal year 2025 results. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1114448/000111444826000007/a260204-99_2.htm
  17. Pharmaceutical Technology. (2026). Novartis’ Q1 sales miss hints at industry’s utilisation of M&A remedies. https://finance.yahoo.com/sectors/healthcare/articles/novartis-q1-sales-miss-hints-111812096.html
  18. AbbVie Inc. (2026, February 4). AbbVie reports full year and fourth quarter 2025 financial results. https://news.abbvie.com/2026-02-04-AbbVie-Reports-Full-Year-and-Fourth-Quarter-2025-Financial-Results
  19. AbbVie Inc. (2026). Form 10-K for fiscal year 2025. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm
  20. AbbVie Inc. (2024). Form 10-K for fiscal year 2023. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1551152/000155115224000011/abbv-20231231.htm
  21. PharmaLive. (2025). AbbVie 2025: Moving on. https://www.pharmalive.com/?p=260996
  22. IntuitionLabs. (2026). Drug patent expirations 2027-2030: Market entry calendar. https://intuitionlabs.ai/articles/drug-patent-expirations-2027-2030-calendar
  23. DrugPatentWatch. (2025). Drug patent expiration: The complete strategic guide to loss of exclusivity, lifecycle management, and the $400 billion cliff. https://www.drugpatentwatch.com/blog/the-impact-of-drug-patent-expiration-financial-implications-lifecycle-strategies-and-market-transformations/
  24. PwC. (2026). Pharmaceutical and life sciences: US deals 2026 midyear outlook. https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html
  25. IQVIA. (2026, July). Biopharma M&A: Mid-year 2026 update. https://www.iqvia.com/locations/emea/blogs/2026/07/biopharma-ma-mid-year-2026-update
  26. PharmaDossier. (2026). 2026 biopharma M&A by the numbers: 33 deals and $134 billion already eclipse all of 2025. https://pharmadossier.com/blog/biopharma-ma-deals-by-the-numbers-2026
  27. Biopharma Wire. (2026, June 12). Biotech M&A reaches $106 billion in 2026 as patent cliff pressure and recovering markets drive record deal pace. https://biopharmawire.com/2026/06/12/biotech-ma-reaches-106-billion-in-2026-as-patent-cliff-pressure-and-recovering-markets-drive-record-deal-pace/
  28. Nasdaq / Zacks. (2025). PFE’s oncology & obesity pipeline position it for post-LOE growth. https://www.nasdaq.com/articles/pfes-oncology-obesity-pipeline-position-it-post-loe-growth
  29. Scrip, Pharma Intelligence. (n.d.). Phase III results could boost Pfizer revenue ahead of Xtandi’s exclusivity loss. https://scrip.pharmaintelligence.informa.com/SC148072/Phase-III-Results-Could-Boost-Pfizer-Revenue-Ahead-Of-Xtandis-Exclusivity-Loss
  30. Salud y Farmacos. (2026). Keytruda, el medicamento de grandes ventas de Merck. Boletin Farmacos: Propiedad Intelectual, 29(2). https://www.saludyfarmacos.org/?p=77132
  31. Synapse, PatSnap. (2026). Novartis full-year 2025 results summary. https://synapse.patsnap.com/drug/37cfd7ee80b14ed7b0237e61c6c2494c
  32. ScienceInsights. (n.d.). When will generic Eliquis be available in the US? https://scienceinsights.org/when-will-generic-eliquis-be-available-in-the-us/
  33. Zacks Investment Research. (2026). J&J posts innovative medicine growth in 2025 amid Stelara patent loss. https://www.zacks.com/stock/news/2841213/jj-posts-innovative-medicine-growth-in-2025-amid-stelara-patent-loss
  34. SingleCare. (n.d.). FDA approves apixaban, first Eliquis generic. https://www.singlecare.com/blog/news/eliquis-generic-apixaban/

Make Better Decisions with DrugPatentWatch

» Start Your Free Trial Today «

Copyright © DrugPatentWatch. Originally published at
DrugPatentWatch - Transform Data into Market Domination